Back to Search
Start Over
Brentuximab vedotin (BV) versus physician’s choice (PC) of methotrexate or bexarotene in adult patients with previously treated CD30-positive cutaneous T-cell lymphoma (CTCL; mycosis fungoides [MF] or primary cutaneous anaplastic large cell lymphoma [pcALCL]): final time to next therapy (TTNT) results from the phase 3 ALCANZA study
- Source :
- Web of Science
- Publication Year :
- 2019
- Publisher :
- Elsevier BV, 2019.
- Subjects :
- CD30 positive
Oncology
Bexarotene
Cancer Research
medicine.medical_specialty
business.industry
Cutaneous T-cell lymphoma
Primary cutaneous anaplastic large cell lymphoma
medicine.disease
Time to next therapy
Internal medicine
CTCL/ Mycosis fungoides
medicine
Methotrexate
Brentuximab vedotin
business
medicine.drug
Subjects
Details
- ISSN :
- 09598049
- Volume :
- 119
- Database :
- OpenAIRE
- Journal :
- European Journal of Cancer
- Accession number :
- edsair.doi.dedup.....8827a2fb72464a274fec2904b955c2c6